A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19

by Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi F. Fagbamigbe, Babatunde A. Adeagbo, Bolanle O. Adefuye, Ajibola Olagunoye, Temitope O. Ojo, Akindele O. Adebiyi, Omobolanle I. Olagunju, Olabode T. Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye O. Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju
Published 2022-09-01